No clinical data could be extracted as the provided text contains only web shop instructions.
Do NT-proBNP and hs-cTnT predict the incidence and prognosis of anthracycline-caused cardiovascular toxicities in Non-Hodgkin's Lymphoma patients?
Non-Hodgkin's Lymphoma (NHL) patients treated with anthracyclines
Measurement of NT-proBNP and hs-cTnT biomarkers
Incidence of symptomatic cardiovascular toxicities (CVTs) and prognosishard clinical
Elevated NT-proBNP and hs-cTnT levels can predict symptomatic cardiovascular toxicities and poor prognosis in NHL patients receiving anthracyclines.
An NT-proBNP-ER ≥ 2.56 or hs-cTnT ≥ 11.68 ng/L, individually or combined, are significant predictors of symptomatic CVTs. Exceeding these thresholds indicates a poor prognosis in NHL patients treated with anthracyclines.
Building similarity graph...
Analyzing shared references across papers
Loading...
Su et al. (Thu,) conducted a other in Non-Hodgkin's Lymphoma. NT-proBNP and hscTnT was evaluated. No clinical data could be extracted as the provided text contains only web shop instructions.
synapsesocial.com/papers/69d893c96c1944d70ce04c29 — DOI: https://doi.org/10.7754/clin.lab.2025.240339
Guangjian Su
Fujian Medical University
Wei Peng
Ministry of Agriculture and Rural Affairs
Yan Chen
Southwest Petroleum University
Clinical Laboratory
Building similarity graph...
Analyzing shared references across papers
Loading...